Answers are grounded in this paper and cite their sources.
The potential of human glucagon-like peptide-1 (hGLP-1) as a therapeutic agent is limited by its high aggregation propensity. We show that hGLP-1 forms amyloid-like structures that are preceded by cytotoxic aggregates, suggesting that aggregation of biopharmaceuticals could present a cytotoxic risk to patients besides the reported increased risk in immunogenicity.
No takes yet. Share an insight, caveat, or question.
Poon et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: